paroxetine for menopause
Systematic review and review evidence indicate paroxetine reduces the frequency (approximately 40-65%) and severity of menopausal vasomotor symptoms.
Hypothesized mechanism
Mechanism not yet characterized in the substrate.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 8 of 10 overall, a strong reading, from a direct rated strong in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Evidence generated in women (female population, ~100% female). (band F1, ×1.00).
Corroboration
Evidence comes from a systematic review (claim 1) and a review article (claims 2-3), but these are syntheses rather than multiple independent primary studies. A single systematic review scores 1, and no large well-powered RCT is cited here to justify a 2.
Rigor
Claim 1 is from a systematic review of SSRI/SNRIs in menopausal women, which qualifies as high-rigor synthesis. The other claims are from review articles summarizing management.
Specificity
Paroxetine is named directly (claims 1-3) and the condition menopause/vasomotor symptoms is explicitly stated, including a quantified reduction in hot flash frequency (claim 2).
Plausibility
The claims assert efficacy in reducing hot flash frequency and severity but do not describe a thermoregulatory/serotonergic mechanism. SSRI action on hypothalamic thermoregulation is plausible but not evidenced in the quotes.
Consistency
All three claims agree in direction, showing paroxetine reduces vasomotor symptom frequency and severity, with a consistent quantified estimate of 40-65% reduction (claim 2).
Independent reading, reported beside the score
One outside model cross-reference is reported alongside the composite score. It is recorded separately and is not combined into the score.
MATRIX cross-reference Top 7%
Every Cure’smachine-learned treatment-probability model, drawn from a biomedical knowledge graph across roughly 1,800 drugs and 22,000 diseases. It provides a model-based estimate of how plausible a drug-disease link is given the structure of biomedical knowledge, reported alongside the substrate’s own evidence.
For this pair. MATRIX places this pair at Top 7%, with a treat-score of 3.39 (higher is better; across the pairs we cover, scores span about 3.1 to 4.5).
Scored over MATRIX’s own entities, confirming the same drug and disease: CHEBI:7936 (drug) and MONDO:0001119 (disease). Validate against the source: Every Cure’s MATRIX dataset ↗.
More on the MATRIX cross-reference and its provenance →Sex-specific pharmacokinetics
Documented differences in how this drug is handled in women, drawn from a primary source, an FDA label or the curated sex-PK literature (Zucker and Prendergast 2020; Soldin and Mattison 2009). It is reported beside the signal and is not part of the composite score; it informs how a result should be interpreted.
Layers not covered for this pair
Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Direct research. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1Paroxetine, citalopram, and escitalopram appear to have the fewest adverse effects. PubMed · PMID 24944075 ↗
- 2paroxetine, citalopram, escitalopram, venlafaxine, and desvenlafaxine are effective in reducing the frequency and severity of hot flashes PubMed · PMID 24944075 ↗
- 3citalopram, desvenlafaxine, escitalopram, gabapentin, paroxetine, and venlafaxine are available and are associated with a reduction in frequency of vasomotor symptoms by approximately 40% to 65% PubMed · PMID 36749328 ↗
- 4nonhormonal medications (such as paroxetine and venlafaxine) also can be effective PubMed · PMID 36749328 ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →